CNR1 and type 2 diabetes mellitus: Macrophage-specific knockdown and/or peripheral blocking of CB1R via the non-CNS-penetrant CB1R inverse agonist JD5037 improved the pathology of type-2 diabetes and re-established normoglycemia by reducing the expression of cardinal NLRP3 inflammasome proteins (201).